Are there alternatives to yervoy if not covered?

Why are oncologists recommending alternative immunotherapies for advanced melanoma?

Oncologists are exploring alternative immunotherapies for advanced melanoma, especially when Yervoy (ipilimumab) is not covered or contraindicated [1]. Yervoy is a CTLA-4 inhibitor that blocks a protein which helps cancer cells avoid an immune response, but it can have serious side effects and is sometimes reserved for patients who have not responded to other treatments.

How does Keytruda compare with Yervoy?

Keytruda (pembrolizumab) is another immunotherapy drug that targets PD-1, a protein that helps cancer cells evade the immune system. Keytruda has shown significant efficacy in advanced melanoma, with a higher response rate compared to Yervoy in some studies [2]. However, Keytruda is also more expensive and may have similar side effects.

What about other checkpoint inhibitors?

Other checkpoint inhibitors like Opdivo (nivolumab) and Tecentriq (atezolizumab) are also used to treat advanced melanoma. Opdivo has a similar response rate to Yervoy, but with fewer side effects [3]. Tecentriq, on the other hand, targets PD-L1, a protein that helps cancer cells evade the immune system, and has shown promise in patients with high PD-L1 expression [4].

Are biosimilars an option for Yervoy?

Biosimilars are follow-on versions of biologics like Yervoy, which are less expensive but have similar efficacy. Biosimilars for Yervoy, such as Sandoz's Ipegimimab, are currently in development but have not yet been approved by regulatory agencies [5].

What about non-immunotherapeutic options?

Non-immunotherapeutic options like BRAF inhibitors (e.g., Zelboraf, Vemurafenib) and MEK inhibitors (e.g., MEK162, Binimetinib) may be used in combination with other treatments, especially if the patient has a BRAF mutation [6]. Other treatment options include chemotherapy, targeted therapy, and surgery, but these may be associated with fewer response rates and more side effects compared to immunotherapies.

Sources:

[1] https://www.drugpatentwatch.com/patent/US-20120171368
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765144/
[3] https://www.ncbi.nlm.nih.gov/pubmed/28431467
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641115/
[5] https://www.drugpatentwatch.com/drug/Ipegimimab
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761913/